Liraglutide vs exenatide: evidence, cost, and legality

Which is better, liraglutide or exenatide?

Liraglutide wins on direct randomized evidence (LEAD-6 and DURATION-6), on cardiovascular outcomes (LEADER hazard ratio 0.87 versus EXSCEL hazard ratio 0.91, not superior to placebo), on label breadth (Saxenda for weight management), and on price now that generics are marketed. Both are FDA approved with human_rct grades; weekly exenatide remains reasonable for someone who will not inject daily and has no access to a newer weekly agent. [1] [2] [3] [4] [6] [9]

How do liraglutide and exenatide compare?

Liraglutide and Exenatide compared by dimension
Dimension	LiraglutideFavored	Exenatide
Head-to-head versus twice daily exenatide [1]	LEAD-6 (464 adults, 26 weeks): liraglutide 1.8 mg daily lowered HbA1c by 1.12 points and weight by 3.24 kg; 54% reached HbA1c below 7%.	Exenatide 10 ug twice daily lowered HbA1c by 0.79 points and weight by 2.87 kg; 43% reached HbA1c below 7%.
Note: Nausea was less persistent and minor hypoglycemia less frequent with liraglutide.
Head-to-head versus once weekly exenatide [2]	DURATION-6 (912 adults, 26 weeks): liraglutide 1.8 mg daily lowered HbA1c by 1.48 points.	Exenatide 2 mg weekly lowered HbA1c by 1.28 points and did not meet noninferiority.
Molecule and half life [5] [7] [8]	Acylated human GLP-1 analog (97% homology), half life about 13 hours, dosed once daily.	Synthetic exendin-4 (about 53% identity to GLP-1), half life about 2.4 hours for the immediate release form; the weekly form uses microspheres.
Cardiovascular outcomes [3] [4]	LEADER (9,340 adults, median 3.8 years): hazard ratio 0.87 for major adverse cardiovascular events; cardiovascular death hazard ratio 0.78.	EXSCEL (14,752 adults, median 3.2 years): hazard ratio 0.91 (95% CI 0.83 to 1.00); noninferior, not superior to placebo.
FDA labeled indications [5] [6] [7] [8]	Victoza for type 2 diabetes; Saxenda 3.0 mg for chronic weight management.	Byetta and Bydureon BCise for type 2 diabetes only (Bydureon BCise also in children 10 and older).
Dosing frequency [5] [7] [8]	Once daily subcutaneous injection, escalated 0.6 mg per week.	Twice daily before meals (Byetta 5 then 10 ug) or once weekly (Bydureon BCise 2 mg).
Side effects that differ [6] [7] [8]	Nausea peaks during escalation; small heart rate increase of 2 to 3 beats per minute.	Injection site nodules with the weekly microsphere form; anti-exenatide antibodies in a substantial minority; not recommended in severe renal impairment.
Note: Both labels (weekly exenatide and liraglutide) carry the thyroid C-cell tumor boxed warning.
Generic availability and cost [8] [9]	Generic liraglutide marketed since December 2024; cash roughly 200 to 500 USD per month for the diabetes strength.	No generic; Byetta and Bydureon BCise list roughly 800 to 1,000 USD per month.
Note: Prices at the verification date change often; see the cost pages.

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

Liraglutide and Exenatide: grade, status, and cost
Attribute	Liraglutide	Exenatide
Class	GLP-1 receptor agonist (acylated analog of human GLP-1, 97% sequence homology, once daily dosing)	GLP-1 receptor agonist (synthetic 39 amino acid exendin-4, originally isolated from Gila monster saliva; twice daily and once weekly extended release forms)
What it is	First daily GLP-1 drug: FDA approved since 2010, about 8% weight loss at 3 mg over 56 weeks, proven heart benefit, now available as a generic.	The first GLP-1 drug, FDA approved in 2005; lowers HbA1c (3 month blood sugar) 0.8 to 1.9 points with 2 to 4 kg weight loss; no proven heart benefit.
Evidence	Evidence: Human RCT evidence	Evidence: Human RCT evidence
FDA status	Regulatory: FDA approved	Regulatory: FDA approved
Compounding	FDA approved products (Victoza January 2010, Saxenda December 2014). FDA approved the first generic liraglutide referencing Victoza in December 2024, and generic products referencing Saxenda followed in 2025, so branded, generic, and authorized generic pens are all on the market. FDA listed liraglutide injection as in shortage in its October 2024 and February 2025 GLP-1 updates, and FDA's Drug Shortages database still lists it as of September 27, 2026 (first posted July 18, 2023; updated September 22, 2026), with Victoza and Saxenda presentations at limited availability and unbranded presentations available. FDA states that a compounded drug may not be identical or nearly identical to an FDA-approved drug unless the approved drug is on FDA's drug shortage list. On April 30, 2026 FDA proposed not to include liraglutide on the 503B bulks list; that proposal was not final as of September 2026. Ask any pharmacy offering compounded liraglutide which FDA rule it relies on.	FDA approved products (Byetta April 2005, Bydureon January 2012, Bydureon BCise October 2017) for type 2 diabetes. Because exenatide is a component of approved drugs, 503A pharmacies may compound it only for a documented patient specific need and may not produce essentially a copy of a marketed product. Exenatide was not part of the semaglutide and tirzepatide shortage era. Product presentations have narrowed over time; check DailyMed for what is currently marketed.
WADA	WADA: Not WADA prohibited	WADA: Not WADA prohibited
Routes	Subcutaneous injection once daily (prefilled pen)	Subcutaneous injection twice daily before meals (immediate release pen), Subcutaneous injection once weekly (extended release microsphere autoinjector)
Typical cost	Manufacturer list price is 1,349.02 USD per month for Saxenda and 543.51 to 815.27 USD per month for Victoza depending on the daily dose (checked 2026-09-22). Generic liraglutide pens cost from about 112 USD per month for the diabetes strength and about 372 USD for the 3 mg weight management generic with a discount card, against average retail prices of about 616 to 924 USD. With commercial insurance the Saxenda savings card can bring a covered prescription to 25 USD. Medicare Part D covers liraglutide for type 2 diabetes but generally not for weight loss alone, and the Medicare GLP-1 Bridge does not include it.	Byetta and Bydureon BCise list at roughly 800 to 1,000 USD per month. With commercial insurance a covered prescription is often 25 to 100 USD per month, and Medicare Part D covers exenatide for type 2 diabetes. No generic is available as of the last verified date, and many formularies now prefer newer GLP-1 agonists.
Last verified	Sep 27, 2026	Sep 27, 2026

Has liraglutide been tested directly against exenatide?

Direct comparisons of Liraglutide and Exenatide
Study	Design and population	Outcome	Grade
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)2009 PMID 19515413	Randomized, open label, parallel group trial, 26 weeksn = 464 Adults with type 2 diabetes on metformin, sulfonylurea, or both	HbA1c minus 1.12 with liraglutide 1.8 mg daily versus minus 0.79 with exenatide 10 ug twice daily; weight minus 3.24 versus minus 2.87 kg	Evidence: Human RCT evidence
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6)2013 PMID 23141817	Randomized, open label, parallel group trial, 26 weeksn = 912 Adults with type 2 diabetes on oral glucose lowering drugs	HbA1c minus 1.48 with liraglutide 1.8 mg versus minus 1.28 with exenatide 2 mg weekly; exenatide did not meet noninferiority	Evidence: Human RCT evidence

What do liraglutide and exenatide cost?

Typical cost of Liraglutide and Exenatide
Dimension	Liraglutide	Exenatide
Typical cost	$112 to $1,349 per month	Byetta and Bydureon BCise list at roughly 800 to 1,000 USD per month. With commercial insurance a covered prescription is often 25 to 100 USD per month, and Medicare Part D covers exenatide for type 2 diabetes. No generic is available as of the last verified date, and many formularies now prefer newer GLP-1 agonists.
Price detail	Liraglutide price by channel	Exenatide price by channel

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

Frequently asked questions

Is liraglutide more effective than exenatide?

Yes, in both direct trials. LEAD-6 found HbA1c reductions of 1.12 versus 0.79 points against twice daily exenatide, and DURATION-6 found 1.48 versus 1.28 points against weekly exenatide, which failed noninferiority. [1] [2]

Which has better heart protection?

Liraglutide. LEADER showed a 13% relative reduction in major adverse cardiovascular events (hazard ratio 0.87) and fewer cardiovascular deaths. EXSCEL showed exenatide was safe but did not significantly reduce events (hazard ratio 0.91). [3] [4]

Do they cause similar weight loss?

In type 2 diabetes they are close: 3.24 kg versus 2.87 kg in LEAD-6. Only liraglutide has a weight management approval, as Saxenda 3.0 mg daily. [1] [6]

Which is easier to take?

Weekly exenatide (Bydureon BCise) requires one injection a week, versus one a day for liraglutide and two a day for Byetta. The weekly exenatide form causes more injection site nodules. [5] [7] [8]

Is either available as a cheaper generic?

Liraglutide is: FDA approved the first generic in December 2024, bringing cash prices down. Exenatide has no generic as of the verification date. [8] [9]

Conditions studied

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style: PeptideAgent. (2026, September 22). Liraglutide vs exenatide: evidence, cost, and legality. https://peptideagent.ai/compare/liraglutide-vs-exenatide
HTML link: <a href="https://peptideagent.ai/compare/liraglutide-vs-exenatide">Liraglutide vs exenatide: evidence, cost, and legality</a>, PeptideAgent, updated September 22, 2026.

Liraglutide vs exenatide

The short answer